Challenges in IPF diagnosis, current management and future perspectives

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 32, Issue , 2015, Pages 28-35

  Wells, Athol U ^a   Costabel, Ulrich ^b   Poletti, Venerino ^c   Crestani, Bruno ^d   Egan, Jim ^e   Margaritopoulos, George ^a   Antoniou, Katerina ^f  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b RUHRLANDKLINIK   (Germany)

^c MORGAGNI PIERANTONI HOSPITAL   (Italy)

^d BICHAT HOSPITAL   (France)

^e MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^f UNIVERSITY OF CRETE   (Greece)

Author keywords

Cryobiopsy; Genetics; Guidelines; Idiopathic pulmonary fibrosis; Pirfenidone; Staging

Indexed keywords

BIOLOGICAL MARKER; NINTEDANIB; PIRFENIDONE; PYRIDONE DERIVATIVE;

ARTICLE; BIOPSY; CRYOBIOPSY; DISEASE SEVERITY; FIBROSING ALVEOLITIS; GENETICS; HEREDITY; HUMAN; LUNG BIOPSY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; RISK BENEFIT ANALYSIS; TREATMENT CONTRAINDICATION; ADVERSE EFFECTS; AGED; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DISEASE MANAGEMENT; FEMALE; IDIOPATHIC PULMONARY FIBROSIS; IMMUNOHISTOCHEMISTRY; LUNG FUNCTION TEST; MALE; MIDDLE AGED; MORTALITY; NEEDLE BIOPSY; NEEDS ASSESSMENT; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

AGED; BIOPSY, NEEDLE; DISEASE MANAGEMENT; DISEASE PROGRESSION; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEEDS ASSESSMENT; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; PYRIDONES; RESPIRATORY FUNCTION TESTS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84938692836     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Raghu G, Collard HR, Egan JJ; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183 (6): 788-824.
2. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD, King TE Jr, Collard HR. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012; 156 (10): 684-91.
3. Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 821-9.
4. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM; CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377 (9779): 1760-9.
5. King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer D, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW, AS-CEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370 (22): 2083-92.
6. Richeldi, L, du Bois RM, Raghu G, et al, for the INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071-82.
7. American Thoracic Society. Idiopathic pulmonary fibrosis: Diagnosis and Treatment. International Consensus Statement Am H Respir Crit Care Med 2000; 161: 646-64.
8. Wells A. The revised ATS/ERS/JRS/ALAT diagnostic criteria for idiopathic pulmonary fibrosis (IPF) - practical implications. Respiratory Research 2013; 14 (Suppl 1): S2.
9. Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ; Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366 (21): 1968-77.
10. Bendstrup E, Maher T, Manali E, Wijsenbeek M. Challenges in the classification of fibrotic ILD. Sarcoidosis Vasculitis and Diffuse Lung Disease 2015; 32 (Suppl 1): 4-9.
11. Latsi PI, du Bois RM, Nicholson AG, Colby TV, Bisirtzoglou D, Nikolakopoulou A, Veeraraghavan S, Hansell DM, Wells AU. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003; 168 (5): 531-7.
12. Rovera F, Imperatori A, Militello P, Morri A, Antonini C, Dionigi G, Dominioni L. Infections in 346 consecutive video-assisted thoracoscopic procedures. Surg Infect (Larchmt) 2003; 4 (1): 45-51.
13. Carrillo G, Estrada A, Pedroza J, Aragón B, Mejía M, Navarro C, Selman M. Preoperative risk factors associated with mortality in lung biopsy patients with interstitial lung disease. J Invest Surg 2005; 18 (1): 39-45.
14. Lettieri CJ, Veerappan GR, Helman DL, Mulligan CR, Shorr AF. Outcomes and safety of surgical lung biopsy for interstitial lung disease. Chest 2005; 127 (5): 1600-5.
15. Kreider ME, Hansen-Flaschen J, Ahmad NN, Rossman MD, Kaiser LR, Kucharczuk JC, Shrager JB. Complications of video-assisted thoracoscopic lung biopsy in patients with interstitial lung disease. Ann Thorac Surg 2007; 83 (3): 1140-4.
16. Utz JP, Ryu JH, Douglas WW, Hartman TE, Tazelaar HD, Myers JL, Allen MS, Schroeder DR. High short-term mortality following lung biopsy for usual interstitial pneumonia. Eur Respir J 2001; 17 (2): 175-9.
17. Park JH, Kim DK, Kim DS, Koh Y, Lee SD, Kim WS, Kim WD, Park SI. Mortality and risk factors for surgical lung biopsy in patients with idiopathic interstitial pneumonia. Eur J Cardiothorac Surg. 2007; 31 (6): 1115-9.
18. Sigurdsson MI, Isaksson HJ, Gudmundsson G, Gudbjartsson T. Diagnostic surgical lung biopsies for suspected interstitial lung diseases: a retrospective study. Ann Thorac Surg 2009; 88 (1): 227-32.
19. Nguyen W, Meyer KC. Surgical lung biopsy for the diagnosis of interstitial lung disease: a review of the literature and recommendations for optimizing safety and efficacy. Sarcoidosis Vasc Diffuse Lung Dis 2013; 30 (1): 3-16.
20. Park JH, Kim DK, Kim DS, Koh Y, Lee SD, Kim WS, Kim WD, Park SI. Mortality and risk factors for surgical lung biopsy in patients with idiopathic interstitial pneumonia. Eur J Cardiothorac Surg 2007 Jun; 31 (6): 1115-9.
21. Utz JP, Ryu JH, Douglas WW, Hartman TE, Tazelaar HD, Myers JL, Allen MS, Schroeder DR. High short-term mortality following lung biopsy for usual interstitial pneumonia. Eur Respir J 2001 Feb; 17 (2): 175-9.
22. Gonnella JS, Hornbrook MC, Louis DZ. Staging of disease. A case-mix measurement. JAMA 1984; 251 (5): 637-44.
23. King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011; 378 (9807): 1949-61.
24. Esbriet (pirfenidone). InterMune UK Ltd. Summary of Product Characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/002154/WC500103049.pdf
25. Esbriet (pirfenidone). InterMune, Inc. Prescribing Information. https://www.esbriet.com/doc/Esbriet-Prescribing-Information.pdf
26. Ofev (nintedanib) Prescribing Information. Boehringer Ingelheim Pharmaceuticals, Inc. http://bidocs.boehringer-ingelheim.com/BI-WebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Ofev/ofev.pdf
27. Xaubet A, Behr J, Bendstrup E, Cottin V, Hirani, Kahler C, Skold M. Review of IPF diagnosis and management recommendations in Europe. Sarcoidosis Vasc Diffuse Lung Dis 2013; 30 (4): 249-61
28. du Bois RM, Weycker D, Albera C, Bradford, W, Costabel U, Katashov A, Lancaster L, Noble P, Raghu G, Sahn S, Szwarcberg J, Thomeer M, Valeyre D, King TE. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184: 459-66.
29. du Bois RM, Albera C, Bradford WZ, Costabel U, Leff JA, Noble PW, Sahn SA, Valeyre D, Weycker D, King TE Jr. 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur Respir J 2014; 43 (5): 1421-9.
30. Mura M, Porretta MA, Bargagli E, Sergiacomi G, Zompatori M, Sverzellati N, Taglieri A, Mezzasalma F, Rottoli P, Saltini C, Rogliani P. Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study. Eur Respir J 2012; 40 (1): 101-9.
31. Costabel U, Bendstrup E, Cottin V, Dewint P, Egan JJ, Ferguson J, Groves R, Hellstrom PM, Kreuter M, Maher M, Molina-Molina M, Nordlind K, Sarafidis A, Vancheri V. Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events. Adv Ther 2014; (4); 375-91.
32. Poletti V, Casoni GL, Gurioli C, Ryu JH, Tomassetti S. Lung cryobiopsies: a paradigm shift in diagnostic bronchoscopy? Respirology 2014a; 19 (5): 645-54.
33. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, McCarthy MI, Ramos EM, Cardon LR, Chakravarti A, Cho JH, Guttmacher AE, Kong A, Kruglyak L, Mardis E, Rotimi CN, Slatkin M, Valle D, Whittemore AS, Boehnke M, Clark AG, Eichler EE, Gibson G, Haines JL, Mackay TF, McCarroll SA, Visscher PM. Finding the missing heritability of complex diseases. Nature 2009; 461 (7265): 747-53.
34. Armanios MY, Chen JJ, Cogan JD, Alder JK, Ingersoll RG, Markin C, Lawson WE, Xie M, Vulto I, Phillips JA 3rd, Lansdorp PM, Greider CW, Loyd JE. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 2007 Mar 29; 356 (13): 1317-26.
35. Tsakiri KD, Cronkhite JT, Kuan PJ, Xing C, Raghu G, Weissler JC, Rosenblatt RL, Shay JW, Garcia CK. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci USA 2007 May 1; 104 (18): 7552-7.
36. van Moorsel CH, van Oosterhout MF, Barlo NP, de Jong PA, van der Vis JJ, Ruven HJ, van Es HW, van den Bosch JM, Grutters JC. Surfactant protein C mutations are the basis of a significant portion of adult familial pulmonary fibrosis in a dutch cohort. Am J Respir Crit Care Med 2010 Dec 1; 182 (11): 1419-25.
37. Markart P, Ruppert C, Wygrecka M, Schmidt R, Korfei M, Harbach H, Theruvath I, Pison U, Seeger W, Guenther A, Witt H. Surfactant protein C mutations in sporadic forms of idiopathic interstitial pneumonias. Eur Respir J 2007 Jan; 29 (1): 134-7.
38. Seibold MA, Wise AL, Speer MC, Steele MP, Brown KK, Loyd JE, Fingerlin TE, Zhang W, Gudmundsson G, Groshong SD, Evans CM, Garantziotis S, Adler KB, Dickey BF, du Bois RM, Yang IV, Herron A, Kervitsky D, Talbert JL, Markin C, Park J, Crews AL, Slifer SH, Auerbach S, Roy MG, Lin J, Hennessy CE, Schwarz MI, Schwartz DA. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 2011; 364 (16): 1503-12.
39. Roy MG, Livraghi-Butrico A, Fletcher AA, McElwee MM, Evans SE, Boerner RM, Alexander SN, Bellinghausen LK, Song AS, Petrova YM, Tuvim MJ, Adachi R, Romo I, Bordt AS, Bowden MG, Sisson JH, Woodruff PG, Thornton DJ, Rousseau K, De la Garza MM, Moghaddam SJ, Karmouty-Quintana H, Blackburn MR, Drouin SM, Davis CW, Terrell KA, Grubb BR, O'Neal WK, Flores SC, Cota-Gomez A, Lozupone CA, Donnelly JM, Watson AM, Hennessy CE, Keith RC, Yang IV, Barthel L, Henson PM, Janssen WJ, Schwartz DA, Boucher RC, Dickey BF, Evans CM. Muc5b is required for airway defence. Nature 2014; 505 (7483): 412-6.
40. Travis WD, Costabel U, Hansell DM, et al, for the ATS/ERS Committee on Idiopathic Interstitial Pneumonias. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188: 733-48.
41. Wuyts WA, Antoniou KM, Borensztajn K, Costabel U, Cottin V, Crestani B, Grutters JC, Maher TM, Poletti V, Richeldi L, Vancheri C, Wells AU. Combination therapy: the future of management for idiopathic pulmonary fibrosis? Lancet Respir Med. 2014; 2 (11): 933-42.
42. European Public Assessment Reports. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fmedicines%2Flanding%2Fepar-search.jsp&mid=WC0b01ac058001d124&searchTab=&already-Loaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&startLetter=O&keyword=Enter+keywords&searchType=name&taxonomyPath=&treeNumber=&searchGenericType=generics
43. FDA news release. FDA approves Ofev to treat idiopathic pulmonary fibrosis. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm418994.htm